ASCO 2023 | Improving the inclusion of patients with multiple myeloma with renal impairment in clinical trials
Claudio Cerchione
• 2 Jun 2023
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, highlights the importance of improving the underrepresentation of specific patient populations with multiple myeloma in clinical trials. Dr Cerchione particularly emphasizes the need to gather more data to better understand the nephrotoxicity of novel immunotherapies like CAR-T therapy in patients with renal impairment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
